Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TNDM 
Tandem Diabetes Care Inc (TNDM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: TNDM (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $22.52
1 Year Target Price $22.52
| 6 | Strong Buy |
| 4 | Buy |
| 10 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 35.29% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.40B USD | Price to earnings Ratio - | 1Y Target Price 22.52 |
Price to earnings Ratio - | 1Y Target Price 22.52 | ||
Volume (30-day avg) 21 | Beta 1.74 | 52 Weeks Range 9.98 - 38.28 | Updated Date 12/5/2025 |
52 Weeks Range 9.98 - 38.28 | Updated Date 12/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.32 | Actual -0.31 |
Profitability
Profit Margin -20.2% | Operating Margin (TTM) -9.17% |
Management Effectiveness
Return on Assets (TTM) -5.94% | Return on Equity (TTM) -109.73% |
Valuation
Trailing PE - | Forward PE 1111.11 | Enterprise Value 1481474014 | Price to Sales(TTM) 1.39 |
Enterprise Value 1481474014 | Price to Sales(TTM) 1.39 | ||
Enterprise Value to Revenue 1.47 | Enterprise Value to EBITDA -10.72 | Shares Outstanding 67802359 | Shares Floating 62041193 |
Shares Outstanding 67802359 | Shares Floating 62041193 | ||
Percent Insiders 1 | Percent Institutions 115.35 |
Upturn AI SWOT
Tandem Diabetes Care Inc
Company Overview
History and Background
Tandem Diabetes Care, Inc. was founded in 2006. It focuses on developing and marketing innovative technologies for people with diabetes, particularly advanced insulin delivery systems.
Core Business Areas
- Insulin Delivery Systems: Development, manufacturing, and commercialization of insulin pumps and related supplies for continuous glucose monitoring (CGM) integration.
- Digital Health Solutions: Creating digital tools and mobile apps to enhance diabetes management and provide personalized insights.
Leadership and Structure
The leadership team includes names like John Sheridan, President and CEO. The organizational structure is hierarchical, with functional departments such as R&D, Marketing, Sales, and Operations.
Top Products and Market Share
Key Offerings
- t:slim X2 Insulin Pump: Tandem's flagship insulin pump, featuring Control-IQ advanced hybrid closed-loop technology that automates insulin delivery based on CGM readings. Competitors include Medtronic (MDT), Insulet (PODD), and Dexcom (DXCM). Market share data varies and is dynamic.
- Control-IQ Technology: An advanced hybrid closed-loop technology, that automates insulin delivery based on CGM readings, which is integrated into the t:slim X2 Insulin Pump. Competitors include Medtronic (MDT), Insulet (PODD).
Market Dynamics
Industry Overview
The diabetes device market is experiencing growth driven by rising diabetes prevalence, technological advancements (CGM, automated insulin delivery), and increasing patient awareness.
Positioning
Tandem is positioned as a leader in automated insulin delivery, with a focus on user-friendly technology and advanced algorithms. The company has gained market share through innovation and strong customer support.
Total Addressable Market (TAM)
The global diabetes care devices market is projected to reach hundreds of billions of USD in the coming years. Tandem is positioned to capture a portion of this market by focusing on innovation in insulin delivery systems and continuous glucose monitoring integration.
Upturn SWOT Analysis
Strengths
- Advanced Technology (Control-IQ)
- User-Friendly Design
- Strong Brand Reputation
- Focus on Innovation
Weaknesses
- Reliance on Single Product Line
- Dependence on Third-Party CGM Integration
- Limited Global Presence (compared to larger competitors)
- Supply Chain vulnerability
Opportunities
- Expanding Global Market Reach
- Developing Next-Generation Technologies
- Partnering with CGM Manufacturers
- Expanding into related digital health solutions
Threats
- Intense Competition
- Reimbursement Pressures
- Technological Disruptions
- Economic downturns
Competitors and Market Share
Key Competitors
- MDT
- PODD
- DXCM
Competitive Landscape
Tandem is competitive with Medtronic and Insulet. Tandemu2019s strength is their innovative technology and user-friendly design.
Major Acquisitions
Capillary Biomedical, Inc.
- Year: 2020
- Acquisition Price (USD millions): 7.5
- Strategic Rationale: Expanded Tandemu2019s product pipeline with innovative infusion set technology.
Growth Trajectory and Initiatives
Historical Growth: Tandem has experienced significant revenue growth in recent years, driven by increased adoption of its t:slim X2 insulin pump and Control-IQ technology.
Future Projections: Future growth projections depend on analyst estimates.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, pursuing international expansion, and investing in research and development.
Summary
Tandem Diabetes Care is a moderately strong company with advanced automated insulin delivery systems and a user-friendly design. Their reliance on one product line is a weakness. They can capitalize on expanding their global reach and develop next-gen technologies. They must watch out for reimbursement pressures.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tandem Diabetes Care Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2013-11-14 | President, CEO & Director Mr. John F. Sheridan | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2650 | Website https://www.tandemdiabetes.com |
Full time employees 2650 | Website https://www.tandemdiabetes.com | ||
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.